2025-05-15-Jefferies-肖特制药（1SXP）_2025年第二季度业绩初步观察_8页_130kb

SCHOTT Pharma Q2'25 Results and Guidance Summary

Key Q2 Performance

• Revenue and EBITDA Growth: Driven by increased share of high-margin drug containment solutions (HVS) and reduced negative FX impact, resulting in strong top and bottom line performance.
• Product Trends: Continued strong demand for glass syringes, offset by weaker polymer syringe demand, which impacted capacity utilization and margin.
• Drivers: Higher demand for HVS products (now 56% of revenue), improved operational efficiency, and positive price trends for glass syringes.

FY25 Guidance

• Confirmed Expectations:
  • Revenue growth expected at a "high SD" organic rate (implied >8.6%).
  • EBITDA margin maintained at approximately 26.9%.
  • HVS share projected at 55% of group revenue.

Segment Analysis

• Drug Containment Solutions (DCS):
  • Q2 revenue growth of 11% CER (€143m), driven by pharma specialty vials and HVS products.
  • EBITDA increased 27% CER to €35m, with a 23.7% margin, supported by HVS mix and cost improvements.
• Drug Delivery Systems (DDS):
  • Revenue increased 8% CER to €109m, led by glass syringe demand.
  • EBITDA margin declined to 34.3%, due to polymer syringe underutilization and ramp-up costs for Hungary capacity.

Valuation and Risks

• Current Rating: HOLD with a €22.93 price target (down from previous levels).
• Key Risks: Challenges in expanding capabilities/capacity, regulatory issues, FX volatility, competition, and dependence on partners.
• Valuation: Based on DCF methodology, with risks including quality issues and continued majority ownership by SCHOTT AG.

Analyst Notes

• Key Themes: Focus on HVS strategy, macro volatility, tariff exposure, and interest expense pressures.
• Conflicts: Jefferies may have conflicts of interest due to business relationships with companies in the sector.